Avacopan, prednisolone and rituximab + Prednisolone and rituximab
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
ANCA Associated Vasculitis (AAV)
Conditions
ANCA Associated Vasculitis (AAV)
Trial Timeline
Nov 15, 2024 → Sep 30, 2028
NCT ID
NCT06611696About Avacopan, prednisolone and rituximab + Prednisolone and rituximab
Avacopan, prednisolone and rituximab + Prednisolone and rituximab is a approved stage product being developed by Kissei Pharmaceutical for ANCA Associated Vasculitis (AAV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06611696. Target conditions include ANCA Associated Vasculitis (AAV).
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06611696 | Approved | Recruiting |
Competing Products
10 competing products in ANCA Associated Vasculitis (AAV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan + Placebo + Rituximab | Novartis | Phase 2 | 52 |
| Rapcabtagene autoleucel + Glucocorticoids | Novartis | Phase 2 | 52 |
| CellCept (mycophenolate mofetil) | Roche | Phase 1 | 33 |
| rituximab + Placebo | Roche | Phase 3 | 77 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Amgen | Phase 2 | 51 |
| Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine | Amgen | Phase 3 | 76 |
| Abatacept (Orencia) | Bristol Myers Squibb | Phase 2 | 51 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy | Kyverna Therapeutics | Phase 1/2 | 33 |
| FT819 + Fludarabine + Cyclophosphamide + Bendamustine | Fate Therapeutics | Phase 1 | 25 |